Lilly Reports Solid Second-Quarter 2009 Results, Raises EP...(NM - - NM ...),Health

Date:7/22/2009

NM - - NM --------- --------- --------- --------- Operating income 1,596.8 1,334.0 20% 3,350.9 2,601.3 29% Net interest income (expense) (45.5) (66.1) (105.7) (122.1) Net other income (expense) 21.4 29.1 10.9 39.9 --------- --------- --------- --------- Other income (expense) (24.1) (37.0) (94.8) (82.2) Income before income taxes 1,572.7 1,297.0 21% 3,256.1 2,519.1 29% Income taxes 346.0 273.6 26% 716.3 533.7 34% --------- --------- --------- --------- Net income $1,226.7 $1,023.4 20% $2,539.8 $1,985.4 28% ========= ========= ========= ========= Earnings per share - basic $1.12 $.94 19% $2.31 $1.82 28% ========= ========= ========= ========= Earnings per share - diluted $1.12 $.94 19% $2.31 $1.81 28% ========= ========= ========= ========= Dividends paid per share $.49 $.47 4% $.98 $.94 4% Weighted-average shares outstanding (thousands) - basic 1,097,184 1,093,778 1,097,195 1,093,831 Weighted-average shares outstanding (thousands) - diluted 1,097,213 1,093,832 1,097,226 1,093,989 NM - not meaningful (a) The second quarter and year-to-date 2009 financial statements have been adjusted to eliminate a special pretax charge of $105.0 million, or $0.06 per share (after-tax), representing the currently probable and estimable exposures in connection with several states' lit
'/>"/>

SOURCE Eli Lilly and Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine news :

1. Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
2. Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo
3. Lilly Sets Date and Conference Call for Second-Quarter 2009 Financial Results Announcement
4. Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
5. Lilly Declares Third-Quarter Dividend
6. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
7. Eli Lilly and Company Announces New Drug Discovery Initiative
8. NAACP & Nine Class Reps File Motion for Class Certification Against Eli Lilly in Pervasive Discrimination Case
9. ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe
10. Bart Peterson to Join Lilly Leadership Team
11. Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration